# Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

> **NCT07027072** · PHASE2 · RECRUITING · sponsor: **NeuroBiogen Co., Ltd** · enrollment: 114 (estimated)

## Conditions studied

- Mild Cognitive Impairment (MCI)
- Mild Dementia
- Alzheimer's Disease

## Interventions

- **DRUG:** KDS2010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07027072
- **Lead sponsor:** NeuroBiogen Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027072, "Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07027072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*